Coronary artery bypass grafting in dialysis patients.

Cardiac disease continues to be a major cause of death in patients undergoing long-term hemodialysis. The results of coronary artery bypass grafting (CABG) for severe coronary artery disease in long-term hemodialysis patients have been studied in a group of 12 patients who underwent CABG between January 1979 and December 1983. Hospital mortality was 8% (1 of 12 patients). This patient died of ventricular arrhythmia. Two late deaths occurred, 1 from peritonitis in a patient undergoing long-term peritoneal hemodialysis and 1 from metastatic renal cell carcinoma. The two postoperative complications (morbidity 17%) consisted of a sternal dehiscence secondary to mediastinitis and a perioperative cerebrovascular accident. Ten of the 11 hospital survivors experienced complete relief from angina. In the other patient the angina became easier to control with medication. Combining this series of patients with those previously reported in the literature allows determination of actuarial survival in a group of 25 patients followed up for 1 to 79 months (mean, 33 months). Actuarial survival was 83% at one year, 69% at three years, and 48% at five years. This is not significantly different from the survival of long-term hemodialysis patients who have coronary disease but have not undergone CABG. It appears that CABG, when performed in long-term hemodialysis patients, is associated with an only slightly greater risk of mortality and morbidity than CABG performed in routine patients. Although CABG provides considerable symptomatic relief of angina, no statistically significant change in actuarial survival can be demonstrated.

Eleven-year experience with composite graft replacement of the ascending aorta and aortic valve.

Between September, 1974, and December, 1985, 127 patients had replacement of the ascending aorta and aortic valve with a composite graft. Annuloaortic ectasia was the most common indication for operation (69 patients), followed by aortic dissection (51 patients). Twenty-four patients (19%) had the Marfan syndrome. Hospital mortality was 4.7%. Emergent operation for acute dissection was the only independent predictor of hospital death (p = 0.03). Reoperation for postoperative hemorrhage was required in 15 patients (11.8%) and for prosthesis-related complications (pseudoaneurysm, prosthetic endocarditis, technical problems, and valve thrombosis) in 16 patients (12.6%). Since we adopted a technique of preclotting the prosthesis with whole blood or albumin plus autoclaving and abandoned the inclusion technique, the reoperation rate has declined substantially. At 5 years, the actuarial freedom from reoperation for any reason on the ascending aorta or aortic valve for the 24 patients in whom this modification was used was 90% and for the remaining 103 patients, 73% (p = 0.17). No reoperations for pseudoaneurysms or technical problems were required in these 24 patients, whereas 10 reoperations for these complications were necessary in the other patients. The mean duration of follow-up was 54 months. The actuarial survival rate at 7 years for the entire group was 65%; for the patients with annuloaortic ectasia, 70%; for those with aortic dissection, 61%; for the patients with the Marfan syndrome, 57%. Actuarial freedom from operation on the remainder of the aorta at 7 years was 89%, but it was 78% for the subgroup with the Marfan syndrome. The satisfactory results with extended follow-up support the continued use of the composite graft technique as the preferred method of treatment for patients with annuloaortic ectasia or recurrent aneurysms of the sinuses of Valsalva and for patients with aortic dissection who require aortic valve replacement.